Investigating the role of immunotherapy for real-world patients with HER2-negative advanced gastric cancer between 2011 and 2023.

ABSTRACT:

Background

Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear.

Objectives

The current study aimed to evaluate the treatment features across various immunotherapy approval periods and investigate the utility of immunotherapy for patients with HER2-negative AGC in daily practice.

Design

Retrospective observational study.

Methods

We retrospectively evaluated the clinical outcomes of patients with HER2-negative AGC who received first-line platinum-based chemotherapy between 2011 and 2023 across different periods of immunotherapy approval in Japan: Group A (pre-immunotherapy approval): 2011-2017; Group B (approved for third-li

SUBMITTER: Shimozaki K 

PROVIDER: S-EPMC11863253 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature